Comparison · NCT02308046-9a2f3c76
Terconazole Vaginal Gel vs Gel Vehicle: Number of Participants With Treatment Emergent Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Terconazole Vaginal Gel vs Gel Vehicle: Number of Participants With Treatment Emergent Adverse Events. Trial comparisons, record NCT02308046-9a2f3c76. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02308046-9a2f3c76
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.382 | 0.294 | 0.479 | wilson | |
| Risk in group 2 | 0.384 | 0.294 | 0.482 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00149 | -0.134 | 0.131 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.996 | 0.701 | 1.41 | log | |
| Odds ratio, group 1 over group 2 | 0.994 | 0.563 | 1.76 | log | |
| Number needed to treat, for one fewer participant with the outcome on Terconazole Vaginal Gel than on Gel Vehicle | 673 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Terconazole Vaginal Gel | One applicator full at bedtime~Terconazole | 39 | 102 | OG000 |
| Group 2 | Gel Vehicle | One applicator full at bedtime~Placebo | 38 | 99 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment Emergent Adverse Events
- Description
- Adverse events were collected at study visits, from subject diaries and from spontaneous reports
- Time frame
- Any time during study participation (up to 30 days)
- Population
- The safety population includes all subjects randomized to treatment and administered at least one dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- Multi-Center Study of New Medications to Treat Vaginal Infections
- NCT number
- NCT02308046
- Phases
- PHASE3
- Conditions
- Vaginal Infection
- Interventions
- Terconazole, Placebo
- Lead sponsor
- Curatek Pharmaceuticals, LLC
- Results first posted
- 2020-07-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02308046?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02308046-9a2f3c76